Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
GET POWR RATINGS... FREE!
KNSA POWR Grades
- KNSA scores best on the Sentiment dimension, with a Sentiment rank ahead of 97.96% of US stocks.
- The strongest trend for KNSA is in Momentum, which has been heading up over the past 179 days.
- KNSA's current lowest rank is in the Stability metric (where it is better than 9.92% of US stocks).
KNSA Stock Summary
- For KNSA, its debt to operating expenses ratio is greater than that reported by only 8.59% of US equities we're observing.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.28 for KINIKSA PHARMACEUTICALS LTD; that's greater than it is for merely 16.73% of US stocks.
- As for revenue growth, note that KNSA's revenue has grown 794.19% over the past 12 months; that beats the revenue growth of 98.56% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to KINIKSA PHARMACEUTICALS LTD are HYPR, BHIL, PLSE, VNRX, and NSPR.
- KNSA's SEC filings can be seen here. And to visit KINIKSA PHARMACEUTICALS LTD's official web site, go to www.kiniksa.com.
KNSA Valuation Summary
- KNSA's EV/EBIT ratio is -29.1; this is 438.37% lower than that of the median Healthcare stock.
- Over the past 55 months, KNSA's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for KNSA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KNSA | 2022-11-25 | 6.2 | 2.9 | 7.7 | -29.1 |
| KNSA | 2022-11-23 | 6.1 | 2.8 | 7.6 | -28.7 |
| KNSA | 2022-11-22 | 6.2 | 2.9 | 7.7 | -29.3 |
| KNSA | 2022-11-21 | 6.3 | 2.9 | 7.8 | -29.5 |
| KNSA | 2022-11-18 | 6.3 | 2.9 | 7.9 | -29.8 |
| KNSA | 2022-11-17 | 6.2 | 2.8 | 7.7 | -29.0 |
KNSA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- KNSA has a Quality Grade of F, ranking ahead of 4.7% of graded US stocks.
- KNSA's asset turnover comes in at 0.023 -- ranking 364th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows KNSA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.023 | 0.68 | -1.083 |
| 2021-03-31 | 0.000 | NA | -0.935 |
| 2020-12-31 | 0.000 | NA | -0.872 |
| 2020-09-30 | 0.000 | NA | -0.783 |
| 2020-06-30 | 0.000 | NA | -0.802 |
| 2020-03-31 | 0.000 | NA | -0.755 |
KNSA Price Target
For more insight on analysts targets of KNSA, see our KNSA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.00 | Average Broker Recommendation | 1.3 (Strong Buy) |
KNSA Stock Price Chart Interactive Chart >
KNSA Price/Volume Stats
| Current price | $16.67 | 52-week high | $17.19 |
| Prev. close | $17.05 | 52-week low | $7.36 |
| Day low | $16.12 | Volume | 256,000 |
| Day high | $16.90 | Avg. volume | 332,840 |
| 50-day MA | $13.89 | Dividend yield | N/A |
| 200-day MA | $11.18 | Market Cap | 1.16B |
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
Latest KNSA News From Around the Web
Below are the latest news stories about KINIKSA PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate KNSA as an investment opportunity.
Kiniksa Pharmaceuticals to Present at Evercore ISI 5th Annual HealthCONx ConferenceHAMILTON, Bermuda, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022 at 10:05 a.m. Eastern Time. A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within app |
Are Medical Stocks Lagging Kiniksa Pharmaceuticals (KNSA) This Year?Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year. |
Wall Street Analysts Predict a 73% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 72.7% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's WhyKiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. |
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Call TranscriptKiniksa Pharmaceuticals, Ltd. (KNSA) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Rachel Frank – Head-Investor Relations Sanj K. Patel – Chief Executive Officer John Paolini – Chief Medical Officer Ross Moat – Chief Commercial Officer Mark Ragosa – Chief Financial Officer Eben Tessari – Chief Operating Officer Conference Call Participants Anupam Rama – JPMorgan Paul Choi – Goldman Sachs Alex Hammond – Bank of America Presentation Operator Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter Earnings Conference Call. At this time, all participan... |
KNSA Price Returns
| 1-mo | 19.97% |
| 3-mo | N/A |
| 6-mo | 92.72% |
| 1-year | 40.68% |
| 3-year | 67.20% |
| 5-year | N/A |
| YTD | 41.63% |
| 2021 | -33.39% |
| 2020 | 59.76% |
| 2019 | -60.63% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...